Elevated serum levels of neopterin but not β2-microglobulin in HIV-1-seronegative injecting drug users

Howard D. Strickler, James F. Blanchard, David Vlahov, Ellen Taylor, Alvaro Munoz, Kenrad Edwin Nelson, Joseph Bernard Margolick

Research output: Contribution to journalArticle

Abstract

Objective: To determine whether injecting drug use is associated with cellular immune activation in the absence of HIV-1 infection. Design: Serum levels of neopterin and β2-microglobulin (β2M) were measured cross-sectionally in injecting drug users (IDU) enrolled in a prospective study. Subjects and methods: Two hundred and nineteen HIV-1-seronegative, healthy heterosexual black male IDU aged 21-49 years were selected from the Baltimore-based AIDS Linked to Intravenous Experiences (ALIVE) study. The possibility of including subjects in the process of seroconverting to HIV-1 was minimized by restricting the study to individuals who remained seronegative 6 months after the specimens used for analysis were collected. Results: Mean serum β2M levels were not statistically different among groups of IDU whose usual pattern of injection was at least once a day for up to 3 consecutive days (daily users; n = 65), less than once per day (less-than-daily users; n = 75), or not at all for at least 2 weeks (non-recent users; n = 79). In contrast, the mean neopterin level was significantly (P = 0.039) greater in daily users (6.17nmol/l) than in the other two groups (5.07 and 5.19nmol/l, respectively, which were not statistically different). These results were not affected, by the frequency of using borrowed non-sterile works or by other demographic and risk factor variables. Conclusions: Frequent injecting drug use may be independently associated with a small elevation of serum neopterin levels, but not β2M levels. Although the occurrence of a type I error in this sample cannot be completely excluded, serum neopterin may be more sensitive than serum β2M in detecting activation of immunocompetent cells associated with frequent injecting drug use in this population.

Original languageEnglish (US)
Pages (from-to)361-367
Number of pages7
JournalAIDS
Volume7
Issue number3
StatePublished - Mar 1993

Fingerprint

Neopterin
Drug Users
HIV-1
Serum
Pharmaceutical Preparations
Baltimore
Heterosexuality
HIV Infections
Acquired Immunodeficiency Syndrome
Demography
Prospective Studies
Injections
Population

Keywords

  • β-microglobulin
  • Cocaine
  • Heroin
  • HIV
  • Injecting drug use
  • Neopterin

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Elevated serum levels of neopterin but not β2-microglobulin in HIV-1-seronegative injecting drug users. / Strickler, Howard D.; Blanchard, James F.; Vlahov, David; Taylor, Ellen; Munoz, Alvaro; Nelson, Kenrad Edwin; Margolick, Joseph Bernard.

In: AIDS, Vol. 7, No. 3, 03.1993, p. 361-367.

Research output: Contribution to journalArticle

Strickler, Howard D. ; Blanchard, James F. ; Vlahov, David ; Taylor, Ellen ; Munoz, Alvaro ; Nelson, Kenrad Edwin ; Margolick, Joseph Bernard. / Elevated serum levels of neopterin but not β2-microglobulin in HIV-1-seronegative injecting drug users. In: AIDS. 1993 ; Vol. 7, No. 3. pp. 361-367.
@article{450ad9d339834e5e89bd825e032fbf78,
title = "Elevated serum levels of neopterin but not β2-microglobulin in HIV-1-seronegative injecting drug users",
abstract = "Objective: To determine whether injecting drug use is associated with cellular immune activation in the absence of HIV-1 infection. Design: Serum levels of neopterin and β2-microglobulin (β2M) were measured cross-sectionally in injecting drug users (IDU) enrolled in a prospective study. Subjects and methods: Two hundred and nineteen HIV-1-seronegative, healthy heterosexual black male IDU aged 21-49 years were selected from the Baltimore-based AIDS Linked to Intravenous Experiences (ALIVE) study. The possibility of including subjects in the process of seroconverting to HIV-1 was minimized by restricting the study to individuals who remained seronegative 6 months after the specimens used for analysis were collected. Results: Mean serum β2M levels were not statistically different among groups of IDU whose usual pattern of injection was at least once a day for up to 3 consecutive days (daily users; n = 65), less than once per day (less-than-daily users; n = 75), or not at all for at least 2 weeks (non-recent users; n = 79). In contrast, the mean neopterin level was significantly (P = 0.039) greater in daily users (6.17nmol/l) than in the other two groups (5.07 and 5.19nmol/l, respectively, which were not statistically different). These results were not affected, by the frequency of using borrowed non-sterile works or by other demographic and risk factor variables. Conclusions: Frequent injecting drug use may be independently associated with a small elevation of serum neopterin levels, but not β2M levels. Although the occurrence of a type I error in this sample cannot be completely excluded, serum neopterin may be more sensitive than serum β2M in detecting activation of immunocompetent cells associated with frequent injecting drug use in this population.",
keywords = "β-microglobulin, Cocaine, Heroin, HIV, Injecting drug use, Neopterin",
author = "Strickler, {Howard D.} and Blanchard, {James F.} and David Vlahov and Ellen Taylor and Alvaro Munoz and Nelson, {Kenrad Edwin} and Margolick, {Joseph Bernard}",
year = "1993",
month = "3",
language = "English (US)",
volume = "7",
pages = "361--367",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Elevated serum levels of neopterin but not β2-microglobulin in HIV-1-seronegative injecting drug users

AU - Strickler, Howard D.

AU - Blanchard, James F.

AU - Vlahov, David

AU - Taylor, Ellen

AU - Munoz, Alvaro

AU - Nelson, Kenrad Edwin

AU - Margolick, Joseph Bernard

PY - 1993/3

Y1 - 1993/3

N2 - Objective: To determine whether injecting drug use is associated with cellular immune activation in the absence of HIV-1 infection. Design: Serum levels of neopterin and β2-microglobulin (β2M) were measured cross-sectionally in injecting drug users (IDU) enrolled in a prospective study. Subjects and methods: Two hundred and nineteen HIV-1-seronegative, healthy heterosexual black male IDU aged 21-49 years were selected from the Baltimore-based AIDS Linked to Intravenous Experiences (ALIVE) study. The possibility of including subjects in the process of seroconverting to HIV-1 was minimized by restricting the study to individuals who remained seronegative 6 months after the specimens used for analysis were collected. Results: Mean serum β2M levels were not statistically different among groups of IDU whose usual pattern of injection was at least once a day for up to 3 consecutive days (daily users; n = 65), less than once per day (less-than-daily users; n = 75), or not at all for at least 2 weeks (non-recent users; n = 79). In contrast, the mean neopterin level was significantly (P = 0.039) greater in daily users (6.17nmol/l) than in the other two groups (5.07 and 5.19nmol/l, respectively, which were not statistically different). These results were not affected, by the frequency of using borrowed non-sterile works or by other demographic and risk factor variables. Conclusions: Frequent injecting drug use may be independently associated with a small elevation of serum neopterin levels, but not β2M levels. Although the occurrence of a type I error in this sample cannot be completely excluded, serum neopterin may be more sensitive than serum β2M in detecting activation of immunocompetent cells associated with frequent injecting drug use in this population.

AB - Objective: To determine whether injecting drug use is associated with cellular immune activation in the absence of HIV-1 infection. Design: Serum levels of neopterin and β2-microglobulin (β2M) were measured cross-sectionally in injecting drug users (IDU) enrolled in a prospective study. Subjects and methods: Two hundred and nineteen HIV-1-seronegative, healthy heterosexual black male IDU aged 21-49 years were selected from the Baltimore-based AIDS Linked to Intravenous Experiences (ALIVE) study. The possibility of including subjects in the process of seroconverting to HIV-1 was minimized by restricting the study to individuals who remained seronegative 6 months after the specimens used for analysis were collected. Results: Mean serum β2M levels were not statistically different among groups of IDU whose usual pattern of injection was at least once a day for up to 3 consecutive days (daily users; n = 65), less than once per day (less-than-daily users; n = 75), or not at all for at least 2 weeks (non-recent users; n = 79). In contrast, the mean neopterin level was significantly (P = 0.039) greater in daily users (6.17nmol/l) than in the other two groups (5.07 and 5.19nmol/l, respectively, which were not statistically different). These results were not affected, by the frequency of using borrowed non-sterile works or by other demographic and risk factor variables. Conclusions: Frequent injecting drug use may be independently associated with a small elevation of serum neopterin levels, but not β2M levels. Although the occurrence of a type I error in this sample cannot be completely excluded, serum neopterin may be more sensitive than serum β2M in detecting activation of immunocompetent cells associated with frequent injecting drug use in this population.

KW - β-microglobulin

KW - Cocaine

KW - Heroin

KW - HIV

KW - Injecting drug use

KW - Neopterin

UR - http://www.scopus.com/inward/record.url?scp=0027462311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027462311&partnerID=8YFLogxK

M3 - Article

C2 - 8471199

AN - SCOPUS:0027462311

VL - 7

SP - 361

EP - 367

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 3

ER -